Attendee search 

Enumeral Biomedical Holdings, Inc. is a Biotechnology company located at 200 CambridgePark Drive, Cambridge, Massachusetts 02140 United States 

Enumeral is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells. Our unique platform allows us to identify and characterize promising new drugs relevant to cancer, infectious and inflammatory diseases, giving us the potential to positively affect millions of patients who are underserved by current therapeutic alternatives.

Nanotech Plus, LLC is a consulting firm focused on the commercialization of advanced materials. Our clients include Fortune 500 companies to startups as well as government agencies. Whether you need information ranging from a potential market for a new product to an assessment of a patent portfolio, we can help. In our 5 year history, we have had a diverse group of clients with a diverse set of needs- but we've been able to satisfy them all.

consulting, marketing patent assessment, due diligence

Our center is the most comprehensive, state-of-the-art laser and cosmetic skin surgery center in the world. Over the past 30 years they have contributed to the development and testing of many devices, fillers and treatments that are now commonly used throughout the world. 

CUNY is home to more than 100 research centers, institutes and consortia, which provide research opportunities for faculty and students, employment, internships, and special events. These centers focus their efforts on a wide range of areas, including aging, applied sciences, corporate integrity, transportation systems, ethnic studies, performing arts, sustainable energy and urban studies, to name a few.

Many institutions reflect CUNY’s support of state-of-the-art education and research, such as the Institute for Ultrafast Spectroscopy and Lasers. Others exemplify the University’s commitment to service and historic preservation, including the Institute for Criminal Justice Ethics at John Jay College and the Gotham Center for New York City History, founded by Pulitzer Prize-winning historian Mike Wallace.

Colliers International Group Inc. (NASDAQ: CIGI; TSX: CIG) is a global leader in commercial real estate services with more than 16,300 professionals operating from 502 offices in 67 countries. With an enterprising culture and significant insider ownership, Colliers professionals provide a full range of services to real estate occupiers, owners and investors worldwide across a broad range of property types, including:

• Brokerage;
• Global corporate solutions;
• Investment sales and capital markets;
• Project management and workplace solutions;
• Property and asset management;
• Consulting, valuation and appraisal services; and,
• Customized research and thought leadership. 

Colliers International has been ranked among the top 100 outsourcing firms by the International Association of Outsourcing Professionals' Global Outsourcing for 10 consecutive years, more than any other real estate services firm.

Simplifying Clinical Research 

Boston Biotech Clinical Research (BBCR) is a strategic clinical innovation organization (SCIO) that offers simplified, customized approaches to planning and conducting clinical research. 
BBCR has a strong knowledge of drug safety, strategic planning and how to maximize the potential of early phase clinical research. 

BBCR helps biotech, pharmaceutical and device companies to deliver capital- and time-efficient clinical development programs – and thereby helps fulfil their product development. 

The innovative approach offered by BBCR facilitates: 
• Strategic clinical plan that, accelerate value creation from the earliest phase of clinical trials 
• Innovative simplified clinical research, using strategies that fully utilize available resources – meeting the requirements of investors, partners and regulators 
• Evidence-based trial strategies, helping to reduce risks and maximize the chances of successful outcomes 
• Design-focused trials that facilitate patients’ recruitment and retention, and cost-effective clinical research

Anavex™ Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer’s, CNS diseases and various types of cancer, which have significant unmet medical needs.

ANAVEX™ 2-73, the Company’s orally available drug candidate developed to treat Alzheimer’s through potential disease modification, has undergone an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg.  Results from pre-clinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties.

A highly encouraging synergistic effect has also been observed between ANAVEX 2-73 and donepezil (Aricept®).  The combined therapeutics, referred to as “ANAVEX™ PLUS,” produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually.

ANAVEX PLUS is believed to be a compelling commercial opportunity.  The clinical trial risk is lower because donepezil (Aricept®) is already on the market, with global sales of $4-billion annually.  Donepezil (Aricept®) is now generic and a patent application has been filed for ANAVEX PLUS which, if granted, would provide protection until 2033.

Headquartered in New York, Anavex is an American publicly traded corporation quoted as AVXL.

Eutropics is advancing personalized medicine by providing novel, predictive diagnostic tests that are uniquely accurate in guiding patient cancer treatments.

» Innovative leading cancer treatment response predictors

» Demonstrated medical utility in blood cancers

» CLIA certified tests for Acute Myeloid Leukemia

» Validated tests for Chronic Lymphocytic Leukemia